Objective: Stereotactic body radiotherapy (SBRT) for early-stage non-small-cell lung cancer (NSCLC) is the standard of care in medically inoperable patients. In very elderly patients, previous studies have shown SBRT to offer excellent local control, though with higher toxicities than in younger populations. We report our institutional experience using SBRT in the definitive management of NSCLC in patients ≥80years old.
Materials And Methods: Using an IRB-approved registry of 158 patients treated with definitive-intent lung SBRT for early-stage NSCLC at our institution between 2010 and 2016, 31 consecutively treated patients ≥80years of age were identified. CTCAEv4 scales were prospectively recorded during follow-ups and utilized for toxicity assessments. Kaplan-Meier estimates were utilized for survival analyses.
Results: For the 31 patients (with 34 lesions) included, median age was 83 (R: 80-93), median ECOG performance status was 2 (R: 0-3), and median follow-up was 15.8months (R: 3.1-48.3). Median PTV size was 24.0cm (R: 5.83-62.1cm). Median prescription dose was 54Gy in 3 fractions (R: 50-60Gy in 3-8 fractions). Local control was 100% at 1year and 92.3% at 2years. Median survival was 29.1months. There were no grade 2-5 toxicities. Grade 1 toxicities included: fatigue in 5 patients (16.1%), asymptomatic (radiographic) pneumonitis in 12 (38.7%), and dyspnea in 2 (6.5%).
Conclusions: Lung SBRT with a BED of ≥100Gy10 for very elderly patients with NSCLC is extremely safe and effective, with inordinately low toxicity rates (zero grade 2-5 toxicities). With stringent dosimetric parameters and planning guidelines, patients ≥80years remain excellent candidates for full-dose SBRT.
Summary: SBRT for early-stage NSCLC is the accepted standard of care in medically inoperable patients, though in many very elderly patients, dose is either de-intensified or withheld for concern of toxicity in the setting of advanced age and competing risks. In this study of our very elderly (≥80years old) early-stage NSCLC patients, we highlight both the extremely high efficacy and tolerability (zero grade 2 or above toxicities) associated with definitive intent SBRT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jgo.2017.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the Robustness of Intensity-modulated Proton Therapy and Proton-arc Therapy Against Interplay Effects of 4D Robust-optimised Plans for Lung Stereotactic Body Radiotherapy.
Clin Oncol (R Coll Radiol)
January 2025
Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Aims: To assess the robustness of 4D-optimised IMPT and PAT plans against interplay effects in non-small cell lung cancer (NSCLC) patients with respiratory motion over 10 mm, and to provide insights into the use of proton-based stereotactic body radiotherapy (SBRT) for lung cancer with significant tumour movement.
Materials And Methods: Fourteen patients with early-stage NSCLC and tumour motion >10 mm were selected. Three hypofraction regimens were generated using 4D robust optimisation with the IMPT and PAT techniques.
Age Is Just a Number? A Retrospective Review of Cause of Death in Patients 85 Years and Over Receiving Lung Stereotactic Ablative Radiotherapy.
J Med Imaging Radiat Oncol
January 2025
Icon Cancer Centre Gold Coast University Hospital, Southport, Queensland, Australia.
Introduction: Patients aged > 85 years are under-represented in research that has established stereotactic body radiotherapy (SBRT) as the standard of care in early stage non-small cell lung cancer (NSCLC) not suitable for or refusing surgery. With an ageing population in Australia, it is important to assess SBRT and cause of death (COD) in elderly patients receiving curative intent lung SBRT.
Methods: This is a multi-centre retrospective review of eligible patients treated across Australia from 2016 to 2022 with curative intent lung SBRT for early stage primary NSCLC, and aged 85 years or over.
Quantitative evaluation of accumulated and planned dose deviations in patients undergoing gated and non-gated lung stereotactic body radiation therapy patients: a retrospective analysis.
Transl Lung Cancer Res
December 2024
Department of Radiation Oncology, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China.
Background: Stereotactic body radiation therapy (SBRT) is crucial for treating early-stage inoperable non-small cell lung cancer (NSCLC) due to its precision and high-dose delivery. This study aimed to investigate the dosimetric deviations in gated (GR) versus non-gated radiotherapy (NGR), analyzing the impact of tumor location, target volume, and tumor motion range on dose distribution accuracy.
Methods: Sixty patients treated with either gated (n=30) or non-gated (n=30) SBRT for early-stage NSCLC were retrospectively analyzed.
Purpose: Radiation Therapy (RT) can modulate the immune system and generate anti-tumor T cells. However, this anti-tumor-activity is countered by radiation-induced immunosuppression (RIIS). Clinical advantages of proactively sparing RT dose to immune rich organs have not previously been evaluated.
View Article and Find Full Text PDFModels and Biomarkers for Local Response Prediction in Early-Stage and Oligometastatic Non-small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy Using Machine Learning.
Cureus
December 2024
Anna and Peter Brojde Lung Cancer Center, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, CAN.
Background A minority of patients receiving stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) are not good responders. Radiomic features can be used to generate predictive algorithms and biomarkers that can determine treatment outcomes and stratify patients to their therapeutic options. This study investigated and attempted to validate the radiomic and clinical features obtained from early-stage and oligometastatic NSCLC patients who underwent SBRT, to predict local response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!